REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

NCT02366026 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV

Interventions

BIOLOGICAL: IR103

Sponsor

Immune Response BioPharma, Inc.